Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: A decade of progress?

Annals of Oncology

Volumn 11, Issue 12, 2000, Pages 1523-1530

  Culine, S ^a   Droz, J P ^b  

^a CENTRE VAL D AURELLE   (France)

^b CENTRE LÉON BÉRARD   (France)

Author keywords

Androgen independent prostate cancer; Chemotherapy; Metastatic prostate cancer

Indexed keywords

2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO[3,4,5 KL]ACRIDINE; 5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; ALPHA INTERFERON; ANDROGEN; ANTINEOPLASTIC AGENT; CARBOPLATIN; DEFEROXAMINE; DOCETAXEL; DOXORUBICIN; EDATREXATE; EPIRUBICIN; ESTRAMUSTINE PHOSPHATE; ETOPOSIDE; FLOXURIDINE; FUMAGILLOL CHLOROACETYLCARBAMATE; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDARUBICIN; IRINOTECAN; KETOCONAZOLE; MITOXANTRONE; NAVELBINE; PACLITAXEL; PREDNISONE; PYRAZINE DIAZOHYDROXIDE; RETINOIC ACID; SURAMIN; TOPOTECAN; UNINDEXED DRUG; VINBLASTINE;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG COST; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MALE; MITOXANTRONE; NEOPLASM METASTASIS; PACLITAXEL; PALLIATIVE CARE; PREDNISOLONE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; TAXOIDS;

EID: 0034490101     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008394823889     Document Type: Review

References (74)

1. Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomised trials with 3283 deaths in 5710 patients
2. Maximum androgen blockade in advanced prostate cancer: A meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens
3. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer
4. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide
5. How is androgen-dependent metastatic prostate cancer best treated?
6. Optimal hormonal therapy for advanced prostatic carcinoma
7. Is 'off-protocol' chemotherapy for androgen-independent carcinoma of prostate warranted?
8. Management of hormone refractory prostate cancer: Current standards and future prospects
9. Treatment options in androgen-independent prostate cancer
10. Apples and oranges: Building a consensus for standardized eligibility criteria and endpoints in prostate cancer clinical trials
11. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-specific Antigen Working Group
12. Hormone-refractory (D3) prostate cancer: Refining the concept
13. The flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostatic cancer
14. Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm
15. Hormone and antihormone withdrawal: Implications for the management of androgen-independent prostate cancer
16. The flare phenomenon on radionucleotide bone scan in patients with metastatic prostatic cancer
17. Some limitations of the radioisotope bone scan in patients with metastatic prostate cancer
18. High-dose intravenous estrogen therapy in advanced prostatic carcinoma: Use of serum prostate-specific antigen to monitor response
19. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer
20. Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer
21. Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor
22. A pharmacokinetically guided phase II study of carboxyamido-triazole in androgen-independent prostate cancer
23. Use of palliative endpoints to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer
24. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative endpoints
25. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone
26. Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: Based on a Canadian randomized trial with palliative endpoints
27. Evaluation of palliative endpoints in oncology clinical trials
28. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study
29. Chemotherapy for prostatic carcinoma
30. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer
31. Carboplatin in advanced hormone refractory prostatic cancer patients
32. A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time
33. Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: A phase II trial
34. Taxol in advanced, hormone-refractory carcinoma of the prostate
35. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: Preliminary results
36. Phase II study of topotecan in metastatic hormone-refractory prostate cancer
37. A phase II trial of irinotecan in hormone-refractory prostate cancer
38. Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma
39. Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer
40. Post-therapy change in prostate-specific antigen levels as a clinical trial endpoint in hormone-refractory prostatic cancer: A trial with 10-ethyl-deaza-aminopterine
41. Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer
42. Pyrazoloacridine for the treatment of hormone-refractory prostate cancer
43. A phase II study of recombinant human alpha-interferon in advanced hormone-refractory prostate cancer
44. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer
45. A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer
46. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor
47. Phase II study of all-trans retinoic acid administered intermittently for hormone refractory prostate cancer
48. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: Results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone
49. Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer
50. Combination chemotherapy in advanced prostate cancer: A silk purse?
51. Estramustine depolymerizes microtubules by binding to tubulin
52. Estramustine binds to a MAP-1 like to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU-145 cells
53. Inhibition of prostate cancer growth by estramustine and etoposide: Evidence for interaction at the nuclear matrix
54. P-glycoprotein binding and modulation of the multidrug resistance phenotype by estramustine
55. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer
56. Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial endpoint for hormone refractory prostatic cancer
57. Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate
58. Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients
59. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer
60. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer
61. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma
62. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate
63. A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer
64. Oral estramustine and oral etoposide for hormone-refractory prostate cancer
65. Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer
66. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer
67. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer
68. Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: A phase II study
69. Evaluation of estramustine phosphate combined with weekly doxorubicin in patients with androgen-independent prostate cancer
70. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial
71. Management of hormone refractory prostate cancer: Current standards and future prospects
72. Novel molecular targets for prostate cancer therapy
73. Prostate cancer vaccines: Current status
74. Gene therapy - The future is here: A guide to the practicing urologist